These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
304 related articles for article (PubMed ID: 36335531)
41. Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions. Dong T; Alencherry B; Ospina S; Desai MY Drug Des Devel Ther; 2023; 17():1097-1106. PubMed ID: 37064432 [TBL] [Abstract][Full Text] [Related]
42. Assessing health-related quality-of-life in patients with symptomatic obstructive hypertrophic cardiomyopathy: EQ-5D-based utilities in the EXPLORER-HCM trial. Xie J; Wang Y; Xu Y; Fine JT; Lam J; Garrison LP J Med Econ; 2022; 25(1):51-58. PubMed ID: 34907813 [TBL] [Abstract][Full Text] [Related]
43. Mavacamten decreases maximal force and Ca Awinda PO; Watanabe M; Bishaw Y; Huckabee AM; Agonias KB; Kazmierczak K; Szczesna-Cordary D; Tanner BCW Am J Physiol Heart Circ Physiol; 2021 Feb; 320(2):H881-H890. PubMed ID: 33337957 [TBL] [Abstract][Full Text] [Related]
44. Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy. Zampieri M; Argirò A; Marchi A; Berteotti M; Targetti M; Fornaro A; Tomberli A; Stefàno P; Marchionni N; Olivotto I Curr Cardiol Rep; 2021 Jun; 23(7):79. PubMed ID: 34081217 [TBL] [Abstract][Full Text] [Related]
45. Evaluating the efficacy and safety of mavacamten in hypertrophic cardiomyopathy: A systematic review and meta-analysis focusing on qualitative assessment, biomarkers, and cardiac imaging. Vyas R; Panchal V; Jain S; Sondhi M; Singh M; Jaisingh K; Thotamgari SR; Thakre A; Modi K PLoS One; 2024; 19(4):e0301704. PubMed ID: 38635724 [TBL] [Abstract][Full Text] [Related]
46. Randomized Trial of Metoprolol in Patients With Obstructive Hypertrophic Cardiomyopathy. Dybro AM; Rasmussen TB; Nielsen RR; Andersen MJ; Jensen MK; Poulsen SH J Am Coll Cardiol; 2021 Dec; 78(25):2505-2517. PubMed ID: 34915981 [TBL] [Abstract][Full Text] [Related]
50. Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial. Wheeler MT; Olivotto I; Elliott PM; Saberi S; Owens AT; Maurer MS; Masri A; Sehnert AJ; Edelberg JM; Chen YM; Florea V; Malhotra R; Wang A; Oreziak A; Myers J JAMA Cardiol; 2023 Mar; 8(3):240-247. PubMed ID: 36652223 [TBL] [Abstract][Full Text] [Related]
51. Characteristics and Outcomes of Elderly Patients With Hypertrophic Cardiomyopathy. Alashi A; Smedira NG; Popovic ZB; Fava A; Thamilarasan M; Kapadia SR; Wierup P; Lever HM; Desai MY J Am Heart Assoc; 2021 Feb; 10(3):e018527. PubMed ID: 33506683 [TBL] [Abstract][Full Text] [Related]
52. Efficacy and safety of mavacamten in treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis. Memon A; Larik MO; Khan Z; Urooj M; Irfan A; Kumari B; Faisal M; Siddiqui R; Tehrim M; Hameed I Future Sci OA; 2023 Dec; 9(10):FSO898. PubMed ID: 37753355 [TBL] [Abstract][Full Text] [Related]
53. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. Seggewiss H; Gleichmann U; Faber L; Fassbender D; Schmidt HK; Strick S J Am Coll Cardiol; 1998 Feb; 31(2):252-8. PubMed ID: 9462563 [TBL] [Abstract][Full Text] [Related]
54. Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy. Tower-Rader A; Ramchand J; Nissen SE; Desai MY Expert Opin Investig Drugs; 2020 Nov; 29(11):1171-1178. PubMed ID: 32897741 [TBL] [Abstract][Full Text] [Related]
55. Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy. Reyes KRL; Bilgili G; Rader F Heart Int; 2022; 16(2):91-98. PubMed ID: 36741099 [TBL] [Abstract][Full Text] [Related]
56. New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy. Woodland M; Al-Horani RA Cardiovasc Hematol Agents Med Chem; 2023; 21(2):78-83. PubMed ID: 36278454 [TBL] [Abstract][Full Text] [Related]
57. Recommendation of mavacamten posology by model-based analyses in adults with obstructive hypertrophic cardiomyopathy. Merali S; Salinger DH; Palmisano M; Sehnert AJ; Thanneer N; Back H; Seroogy JD; Gretler DD; Roy A; Perera V CPT Pharmacometrics Syst Pharmacol; 2024 May; ():. PubMed ID: 38695527 [TBL] [Abstract][Full Text] [Related]
58. Symptom assessment and exercise impairment in surgical decision making in hypertrophic obstructive cardiomyopathy: Relationship to outcomes. Desai MY; Smedira NG; Bhonsale A; Thamilarasan M; Lytle BW; Lever HM J Thorac Cardiovasc Surg; 2015 Oct; 150(4):928-35.e1. PubMed ID: 26318357 [TBL] [Abstract][Full Text] [Related]
59. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Fananapazir L; Epstein ND; Curiel RV; Panza JA; Tripodi D; McAreavey D Circulation; 1994 Dec; 90(6):2731-42. PubMed ID: 7994815 [TBL] [Abstract][Full Text] [Related]